Medication usage and the risk of neoplasia in patients with Barrett's esophagus.

[1]  C. Bain,et al.  Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus , 2008, Cancer Epidemiology Biomarkers & Prevention.

[2]  O. Ogunwobi,et al.  Statins Inhibit Proliferation and Induce Apoptosis in Barrett's Esophageal Adenocarcinoma Cells , 2008, The American Journal of Gastroenterology.

[3]  H. Behlouli,et al.  Statins and cancer risk. , 2008, The American journal of medicine.

[4]  A. Shar,et al.  Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. , 2007, Journal of the National Cancer Institute.

[5]  T. Levin,et al.  Barrett's Esophagus and Medications that Relax the Lower Esophageal Sphincter , 2006, The American Journal of Gastroenterology.

[6]  B. Cooper,et al.  Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence , 2006, Alimentary pharmacology & therapeutics.

[7]  Carissa A. Sanchez,et al.  Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. , 2005, The Lancet. Oncology.

[8]  A. Bhattacharyya,et al.  Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus , 2004, American Journal of Gastroenterology.

[9]  M. Hendrickse,et al.  Daily use of non‐steroidal anti‐inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma , 2004, Alimentary pharmacology & therapeutics.

[10]  B. Shadbolt,et al.  Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus , 2004, The Medical journal of Australia.

[11]  Samantha Sharpe,et al.  Cancer Research UK , 2002, Nature Cell Biology.

[12]  Kenneth K Wang,et al.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. , 2002, Gastroenterology.

[13]  S. Attwood,et al.  Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence , 2001, American Journal of Gastroenterology.

[14]  L. Blais,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.

[15]  N. Shepherd.  Barrett's oesophagus and proton pump inhibitors: a pathological perspective , 2000, Gut.

[16]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[17]  J. Fraumeni,et al.  The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. , 1995, JAMA.

[18]  K. Kerlikowske,et al.  Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. , 2003, Gastroenterology.

[19]  Ph.D. Manuel Pera M.D..  Trends in Incidence and Prevalence of Specialized Intestinal Metaplasia, Barrett’s Esophagus, and Adenocarcinoma of the Gastroesophageal Junction , 2003, World Journal of Surgery.